|
|
 |
|
Viewing report
|
|
|
|
Multi Client Study: Opportunities Assessment for the Hepatitis C Therapeutics Market in Australia
Frost & Sullivan, Dec 2009, Pages: 68
This Frost & Sullivan research service titled Multi Client Study: Opportunities Assessment for the Hepatitis C Therapeutics Market in Australia provides an update on the epidemiology of Hepatitis C, current diagnostic and treatment practices, as well as market landscape in terms of major participants and future trends. This study aims to support manufacturers in decision making as well as identifying and prioritizing opportunities in Australia. This research service analyzes the major issues and factors affecting the growth of the Hepatitis C therapeutics market. A list of current and pipeline products for Hepatitis C therapeutics is also furnished.
Market Overview
Better Clarity on Diagnosis Enables the Introduction of Novel Treatments in the Hepatitis C Therapeutics Market in Australia
Spirited efforts to raise disease awareness have increased the number of diagnosed cases and expanded the base of patients available for treatment. Physicians expect the rate of diagnosis to continue rising in Australia due to heightening of awareness among general practitioners regarding screening and treatment for Hepatitis C. Screening of Hepatitis C patients in Australia, especially among illicit drug users, has resulted in a spike in the number of diagnosed cases of Hepatitis C virus (HCV). In 2009, an estimated 77 percent of patients-at-risk with Hepatitis C were diagnosed, and this figure is expected to reach up to 87 percent by 2016. Higher efficacy and safety are the most preferred drug attributes. Physicians expect new oral anti-virals (boceprevir and telaprivir) and interferon with improved safety (albuferon) to be launched by 2013 in Australia. According to physicians, prevalence had increased rapidly in the early 2000s, but the rate had declined over the years and the pace is likely to slacken in the future owing to a major disruption to the supply of heroin in Australia in 2001. 'The Australian Government has unleashed Initiatives to address the Hepatitis C virus in the country, allocating $14.3 million (Australian dollar 17 million) for Hepatitis C education and prevention over the 2007-2011 period,' notes the analyst of this research service. 'State and territory governments also have substantial budgets for Hepatitis C prevention and education.' The priority action areas identified as part of the National Hepatitis C Strategy are prevention, education; diagnosis, treatment, surveillance; and research. The Government is avidly addressing healthcare workforce development as well as issues surrounding discrimination and stigma.
Although there is a high diagnosis rate in Australia, only a paltry 3 percent of diagnosed patients pursue treatment owing to a lack of patient understanding about treatment options. According to physicians, one of the main reasons for such a large proportion of diagnosed patients left untreated is that they are predominantly from disadvantaged groups such as illicit drug users, aboriginal people, those serving prison sentences, and some migrant groups, which do not have access to conventional healthcare. Often the reason is real or perceived stigma and discrimination. Aside from this, there is a great deal of angst about debilitating side effects, frequent dosing, and lackluster efficacy of the existing HCV treatments, especially for those afflicted with genotype 1. Moreover, there is a belief that a liver biopsy is required to receive treatment, which deters patients from undergoing treatment.
To circumvent the challenges clouding the market landscape, companies must offer treatment options that expedite efficiency, have fewer side effects, and are cost efficient. Patients should be made aware of their disease status and encouraged to remain compliant. 'As more improvements are required to educate at risk patients, public and private organizations including pharmaceutical companies must up the ante to spread awareness,' notes the analyst of this research service. 'Greater information outreach will help patients obtain the right mode of treatment and ultimately stem the onslaught of the Hepatitis C virus in Australia.'
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Hepatitis C Therapeutics Market—Thailand
Multi Client Study: Opportunities Assessment for the Hepatitis C Therapeutics Market in Indonesia
Hepatitis C Therapeutics Market – Taiwan
Global Hepatitis C Virus (HCV) Market– An Analysis
Hepatitis C Viral Infection - After Protease Inhibitors What Is Next?
Hepatitis Therapeutics Market to 2016 - Strong Hepatitis-C Pipeline and Cost Effective Treatments will Drive the Global Hepatitis Market
Hepatitis C Virus - Protease Inhibitors Bring Change in the Treatment Paradigm for Hepatitis C Virus Infection - What Next?
Viral Hepatitis
Antivirals Market to 2016 - Antiretroviral Agents and Combination Therapies to be Major Drivers HIV and Hepatitis C Markets
Emerging Microbiology Tests and Companies Developing New Technologies and Products
|
|
|
|
